NCT06809426Completed
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 5 Feb 2025
Brief summary (registry, in English)
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 13 (actual)
- First submitted
- 23 Jan 2025
- Start date
- 21 Aug 2023
- Primary completion date
- 14 Oct 2024
- Lead sponsor
- Affiliated Hospital of Jiangnan University
- Diseases
- Prostate cancer
- NCT number
- NCT06809426
What you commit to
- Study type: Interventional
- Participants enrolled: 13
- From 21 Aug 2023 to the primary completion date, 14 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who did not meet the requirements as assessed by the investigator.
Who the study is looking for
- ≥18 years old, male.
- histologically or cytologically defined prostate cancer, the patients have not been treated or have exhausted all treatment.
- meet the Prostate Cancer Working Group 3 (PCWG3) diagnosis of metastatic desmoplasia-resistant prostate cancer (mCRPC), including: a) the presence of a desmoplasia level of serum testosterone (serum testosterone \<50 ng/dL or 1.7 nmol/L); b) and the presence of one of the following: - serum PSA progression: PSA \>1 ng/mL and 2 consecutive rises in PSA 1 week apart, 2 greater than 50% of the nadir; or a bone scan suggestive of ≥2 new bone lesions; or CT or MRI suggestive of progression of soft tissue lesions (RECIST 1.1).
- a physical status score of ≤2 according to Eastern Cooperative Oncology Group (ECOG) criteria.
- PSMA positivity confirmed by 68Ga -PSMA PET/CT.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Affiated Hospital of Jiangnan University Coordinator of this site? Confirm its status | Wuxi | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.